Bulk Pharmaceutical API Sources for XELODA

Bulk Pharmaceutical API Sources for XELODA

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		60953
MolPort		MolPort-005-938-254
ABI Chem		AC1L1U83
ABI Chem		AC1Q4KU8
Oakwood Products		048966
ChemMol		44005293
ChemMol		49409780

Bulk Active Pharmaceutical Ingredient (API) Sources for XELODA

Last updated: February 19, 2026

This report identifies and analyzes key bulk active pharmaceutical ingredient (API) suppliers for XELODA (capecitabine), a widely used oral chemotherapy drug. Analysis focuses on supplier capabilities, regulatory compliance, and market presence.

What is XELODA and its API?

XELODA is the brand name for capecitabine, an orally administered chemotherapeutic agent. It is a prodrug of 5-fluorouracil (5-FU), an antimetabolite used in the treatment of metastatic breast and colorectal cancers. The primary active pharmaceutical ingredient (API) for XELODA is capecitabine.

Capecitabine is synthesized through a multi-step chemical process. Its chemical name is N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine. The molecular formula is C15H22FN3O6, and its molecular weight is 359.35 g/mol.

The global demand for XELODA is driven by its efficacy in treating various solid tumors, particularly metastatic breast and colorectal cancers. This demand translates directly to a consistent need for high-quality, reliably sourced capecitabine API.

Key API Suppliers for Capecitabine

The market for capecitabine API is characterized by a mix of large, established pharmaceutical ingredient manufacturers and specialized chemical synthesis companies. These suppliers operate under stringent regulatory frameworks, including Good Manufacturing Practices (GMP), to ensure product quality and safety.

Supplier Company Name	Country of Origin	Primary Manufacturing Site Location(s)	Key Certifications (Relevant to API)	Notes
Sun Pharmaceutical Industries Ltd.	India	Multiple sites in India	US FDA, EDQM, WHO GMP	Major generic pharmaceutical manufacturer with significant API production capacity.
Dr. Reddy's Laboratories Ltd.	India	Multiple sites in India	US FDA, EDQM, PMDA	A leading integrated global pharmaceutical company with strong API development and manufacturing.
Aurobindo Pharma Limited	India	Multiple sites in India	US FDA, EDQM, TGA, Health Canada	A vertically integrated pharmaceutical company with a broad API portfolio.
Teva Pharmaceutical Industries Ltd.	Israel	Multiple sites globally	US FDA, EDQM, EMA	A global leader in generic pharmaceuticals with extensive API manufacturing capabilities.
Cipla Limited	India	Multiple sites in India	US FDA, EDQM, WHO GMP	One of India's oldest pharmaceutical companies, with a strong focus on API production.
Hetero Labs Limited	India	Multiple sites in India	US FDA, EDQM	A significant player in the generics and API market, with a focus on complex molecules.
Divi's Laboratories Limited	India	Multiple sites in India	US FDA, EDQM, PMDA	Specializes in custom synthesis and the production of high-volume APIs.
MSN Laboratories Pvt. Ltd.	India	Multiple sites in India	US FDA, EDQM	A rapidly growing pharmaceutical company with substantial API manufacturing.
Laurus Labs Limited	India	Multiple sites in India	US FDA, EDQM, PMDA	Focuses on API development and manufacturing across various therapeutic areas.

Data sourced from company reports, regulatory filings, and industry databases. Specific site details may vary and are subject to change.

Supplier Capabilities and Regulatory Landscape

Manufacturers supplying capecitabine API must adhere to strict quality control and regulatory standards. The primary regulatory bodies influencing API manufacturing for global markets include the U.S. Food and Drug Administration (FDA), the European Directorate for the Quality of Medicines & HealthCare (EDQM), and national health authorities like Japan's Pharmaceuticals and Medical Devices Agency (PMDA) and Europe's European Medicines Agency (EMA).

Key certifications and compliance measures include:

• Current Good Manufacturing Practices (cGMP): Essential for all API manufacturers. Audits by regulatory agencies ensure compliance with cGMP guidelines covering facility design, equipment, personnel, production processes, quality control, and record-keeping.
• Drug Master Files (DMFs): Manufacturers typically file DMFs with regulatory agencies like the FDA. These confidential documents contain detailed information about the manufacturing process, facilities, and quality control of the API. Pharmaceutical companies reference these DMFs when seeking marketing authorization for their finished drug products.
• Certificates of Suitability to the Monographs of the European Pharmacopoeia (CEP): Issued by the EDQM, a CEP demonstrates that the API complies with the requirements of the European Pharmacopoeia. This simplifies the regulatory process for drug products intended for the European market.
• Inspections and Audits: Regular inspections by regulatory bodies and audits by potential customers are standard. Suppliers with a history of successful inspections and audits are generally considered more reliable.

India has emerged as a dominant global supplier of APIs, including capecitabine, due to its robust chemical synthesis expertise, cost-competitiveness, and strong regulatory compliance infrastructure. Many Indian manufacturers have invested heavily in upgrading their facilities to meet international standards.

Market Dynamics and Competitive Landscape

The market for capecitabine API is competitive, with pricing influenced by production volume, purity levels, regulatory compliance, and long-term supply agreements. Genericization of XELODA has led to increased competition among API suppliers aiming to secure contracts with generic drug manufacturers.

Factors influencing supplier selection:

• API Purity and Quality: Manufacturers require API with high purity (>99%) and consistent particle size distribution, critical for tablet formulation and bioavailability.
• Regulatory Compliance: A strong regulatory track record and readily available documentation (DMFs, CEPs) are paramount.
• Supply Chain Reliability: Consistent production capacity and a robust supply chain are necessary to avoid drug shortages.
• Cost-Effectiveness: While quality is prioritized, competitive pricing is a significant consideration for generic drug manufacturers.
• Technical Support: Suppliers offering strong technical support for formulation and regulatory filings are preferred.

The landscape includes both large, vertically integrated pharmaceutical companies that produce APIs for their own finished dosage forms and also for external sale, and specialized API manufacturers focused solely on bulk ingredient production.

Emerging Trends and Future Outlook

The demand for capecitabine API is expected to remain stable, driven by the continued use of XELODA in oncology. Trends impacting the API market include:

• Increased Scrutiny on Supply Chain Integrity: Regulatory agencies and pharmaceutical companies are placing greater emphasis on supply chain security and traceability to prevent counterfeit or substandard APIs from entering the market.
• Advancements in Synthetic Processes: Ongoing research aims to optimize synthetic routes for capecitabine, potentially leading to improved yields, reduced environmental impact, and lower production costs.
• Geographic Diversification of Sourcing: While India remains a dominant supplier, some pharmaceutical companies are exploring diversification of their API sourcing to mitigate geopolitical or supply chain risks, potentially increasing opportunities for manufacturers in other regions that meet stringent quality standards.
• Focus on Sustainability: Growing pressure for environmentally sustainable manufacturing practices may influence the choice of API suppliers, favoring those with demonstrated commitment to green chemistry and waste reduction.

Key Takeaways

• Capecitabine API is primarily sourced from established manufacturers, with India being a dominant production hub.
• Key suppliers possess strong regulatory compliance records, including US FDA and EDQM certifications, and maintain comprehensive DMFs.
• Purity, consistent quality, supply chain reliability, and cost-effectiveness are critical selection criteria for API purchasers.
• The market is competitive, with genericization driving demand for cost-effective, high-quality API.
• Future trends include increased focus on supply chain integrity, sustainable manufacturing, and potential geographic diversification of sourcing.

Frequently Asked Questions

What are the primary regulatory requirements for capecitabine API manufacturers?

Manufacturers must adhere to Current Good Manufacturing Practices (cGMP). They typically file Drug Master Files (DMFs) with regulatory bodies like the U.S. Food and Drug Administration (FDA) and may obtain Certificates of Suitability to the Monographs of the European Pharmacopoeia (CEP) from the EDQM.

How does the purity of capecitabine API affect its use?

High purity (typically above 99%) and consistent particle size distribution are critical for capecitabine API. These factors directly impact the bioavailability and efficacy of the final XELODA drug product, ensuring predictable therapeutic outcomes.

What is the role of Drug Master Files (DMFs) in the capecitabine API supply chain?

DMFs contain confidential detailed information about the manufacturing process, quality control, and facility operations for capecitabine API. Pharmaceutical companies reference these DMFs in their marketing authorization applications, allowing regulatory agencies to review the API's manufacturing without disclosing proprietary information to the drug product applicant.

Are there significant price variations among capecitabine API suppliers?

Price variations can occur due to production volume, economies of scale, the cost of raw materials, the level of regulatory compliance and certifications held, and the supplier's overall market position. Long-term supply agreements and bulk purchase volumes can also influence pricing.

What are the main risks associated with sourcing capecitabine API?

Primary risks include potential supply chain disruptions due to geopolitical events, manufacturing issues, or regulatory non-compliance. Risks also encompass variations in API quality, counterfeiting, and reliance on a limited number of key suppliers, which can impact drug availability.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA website] (Note: Specific URL changes frequently; general search for "FDA Drug Master Files" is recommended). [2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability (CEP). Retrieved from [EDQM website] (Note: Specific URL changes frequently; general search for "EDQM Certificate of Suitability" is recommended). [3] World Health Organization. (2010). Good manufacturing practices for pharmaceutical products: main principles. WHO Technical Report Series, 961. [4] Company Annual Reports and Investor Relations Documents for Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Teva Pharmaceutical Industries Ltd., Cipla Limited, Hetero Labs Limited, Divi's Laboratories Limited, MSN Laboratories Pvt. Ltd., and Laurus Labs Limited. (Specific report years vary). [5] Various pharmaceutical industry market research reports on the global API market for oncology drugs. (Specific report names and publishers vary).